Patients with residual lung shadow during recovery from novel coronavirus infection
Conditions
Interventions
Control group:Take blank control, daily drinking of conventional drinking water, no less than 2000ml per day, for 4 weeks.
Experimental group:The patient was treated with spectral water combined with infrared spectral irradiation.
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =18 years old, gender unlimited; 2. The acute exudative lesions of hospitalized patients with moderate and severe COVID-19 showed significant improvement in lung imaging after antiviral treatment, meeting the discharge criteria (refer to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial version 10)); 3. Before randomization, the lung imaging findings of patients showed multiple patchy infectious lesions, ground-glass density lesions of the lung, irregular fiber shadow, fibrotic changes, pulmonary nodules and other characteristic lesions; 4. Patients who have previously received prophylaxis or antiviral therapy for COVID-19 (including investigational therapy) should be enrolled in this study after 5 half-lives (PAXLOVID should be at least 48 hours apart, azvudine should be at least 72 hours apart); 5. Sign informed consent and be willing to comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1. Patients with heart and renal failure and patients with dysregulation of antiriuretic secretion syndrome; (2) Patients with embedded medical electronic instruments such as cardiac pacemakers or other electronic instruments for life support, and patients with dynamic monitoring instruments such as electronic blood glucose testers or dynamic ECG monitors; 3. Patients with bleeding tendency, high fever, active tuberculosis, acute suppurative inflammation, and malignant tumor; 4. People with skin sensory disorders; 5. There are skin grafts and scar areas in the irradiation area; 6. Patients with arterial obstructive disease, severe stage III hypertension and coronary heart disease; 7. Lactating women, pregnant women, or women of childbearing age whose urine pregnancy test is positive; 8. Subjects deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary CT ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary function change;Changes of C-reactive protein, blood routine, liver and kidney function, coagulation function, KL-6;Changes of procalcitonin;6 minutes walking distance;Borg subjective fatigue perception;Leicester cough questionnaire;The 12-item short form health survey version;Product operation satisfaction;Instrument defect evaluation; | — |
Countries
China
Contacts
Public ContactYu Chen
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed